Venous Thromboembolism
News from the FDA/CDC
FDA: Safety signal emerged with higher dose of tofacitinib in RA study
The FDA is working with Pfizer to better understand how the signal affects patients and how the drug should be used, the agency said in a...
From the Journals
ICYMI: Rivaroxaban reduces VTE incidence in ambulatory cancer patients
However, the reduction lost significance if treatment with rivaroxaban was halted.
From the Journals
Supplementary compression doesn’t improve DVT odds in critically ill
SAN DIEGO – The procedure carries few risks, aside from patient discomfort.
From the Journals
ICYMI: Andexanet alfa reduces anti–factor Xa activity from apixaban, rivaroxaban
Reductions were similar for those receiving apixaban and rivaroxaban.
From the Journals
Venous thromboembolism risk elevated in ankylosing spondylitis patients
AS patients showed a significantly increased risk of VTE, compared with controls, especially during the first year after diagnosis.
Conference Coverage
Biomarkers predict VTE risk with menopausal oral hormone therapy
CHICAGO – Pretreatment high D-dimer spells 500% increased VTE risk on oral hormone therapy.
Conference Coverage
Immunotherapy’s cardiac effects require early monitoring, management
Immune checkpoint inhibitors and chimeric antigen receptor T cells can be highly effective against cancer, but can also harm the heart and...
Latest News
New recall for CoaguChek test strips issued
These CoaguChek XS PT test strips were distributed by Terrific Care and Medex but weren’t included in Roche Diagnostics’ original recall.
From the Journals
COPD linked to higher in-hospital death rates in patients with PAD
COPD was an independent predictor of in-hospital death and of pulmonary embolism in PAD patients.
From the Journals
Treprostinil improves function for complex PAH patients
Adults with CTEPH who received a high dose of subcutaneous treprostinil improved significantly, compared with baseline.
From the Journals
Most oral HRT linked to increased VTE risk